OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI), announced Monday morning that the Phase 3 SYNERGY trial testing the combination of custirsen and standard first line docetaxel/prednisone therapy failed to meet the primary end point of the test. The news about the Phase 3 trial caused the company’s stock price to tumble about 60% by the end of the trading session yesterday. OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI), shares after opening at $3.85 moved to $4.00 on last trade day and at the end of the day closed at $3.88. Company price to sales ratio in past twelve months was calculated as 1.91and price to cash ratio as 1.46. OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI), showed a negative weekly performance of 62.80%.
In the preliminary filing, DARA Biosciences Inc (NASDAQ:DARA), reported it wants to sell about 8 million shares based on an assumed per unit price of $2.48, which was the closing price on April 16. The larger $32 million figure is reported as a way to calculate a registration fee with the Securities and Exchange Commission. DARA Biosciences Inc (NASDAQ:DARA), shares fell 3.91% in last trading session and ended the day on $1.72. DARA Biosciences Inc (NASDAQ:DARA), return on equity ratio is recorded as -122.80%and its return on assets is -107.20%. DARA Biosciences Inc (NASDAQ:DARA), yearly performance is -55.90%.
On April 30, 2014, Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG), announced that J. Kevin Buchi, President and Chief Executive Officer, will present at the Deutsche Bank 39th Annual Healthcare Conference on Wednesday, May 7, 2014 at 1:30 p.m. Eastern Time in Boston. Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG), shares moved down 3.55% in last trading session and was closed at $5.70, while trading in range of $ 5.57 – 6.15. Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG), year to date (YTD) performance is -40.13%.
Leerink Swann initiated coverage on shares of Corium International Inc (NASDAQ:CORI), in a research note issued on Monday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating and a $8.19 price target on the stock. Leerink Swann’s price target indicates a potential upside of 9.64% from the company’s current price. Corium International Inc (NASDAQ:CORI), weekly performance is -7.70%. On last trading day company shares ended up $7.55. Corium International Inc (NASDAQ:CORI), distance from 50-day simple moving average (SMA50) is -5.68%.